Comparison of DVd and VAdM in the treatment of newly diagnosed multiple myeloma

VernacularTitle:DVd方案与VAdM方案对初治多发性骨髓瘤的疗效观察
Author: Beihui HUANG ; Juan LI ; Ying ZHAO ; Jingli GU ; Chang SU ; Guocai ZHANG ; Waiyi ZOU
Publication Type:Journal Article
Keywords: DVd; VAdM; Multiple myeloma; Treatment
From: Journal of Leukemia & Lymphoma 2008;17(5):342-345
CountryChina
Language:Chinese
Abstract: Objective To compare effects and toxicities of DVd and VAdM regimen for newly diagnosed multiple myeloma.nethods 17 newly diagnosed active multiple myeloma received DVd treatment,dexamethasone(20 mg/d)on days 1～4 as an intravenous infusion.16 newly diagnosed active multiple myeloma on days 1～4 plus melphalan(12 mg/d)as an intravenous infusion.Results Objective response rates(DVd,76.5%;VAd,81.3%,P=0.737)were similar between the two treatment groups.In the DVd group,the mean time to max response was shorter than the VAdM group[(3.2±1.7)months vs.(4.6±1.0)months,P=0.039].DVd was associated with low Grade 3/4 neutropenia(23.5% vs.68.8%,P=0.015),less use of G-CSF(11.8% vs.62.5%,P=0.004),less use antibiotic(11.8% vs.37.5%,P=0.118),lower incidence of hospitalization for adverse events(37.5% vs.17.6%,P=0.259),but more hand-foot syndrome.Coilcinsion The DVd regimen demonstrated similar efficacy compared with VAdM,while with less toxicity and supportive care,which might be used as a modified VAd regimen for newly diagnosed myeloma.